The greatest risk of all-grade PAEs in patients with skin cancer was related to anti-PDL1 plus targeted therapy drug, which differed significantly from the other interventions except for targeted therapy drug and anti-PD1 plus anti-CTLA4. The gene discussed is PDCD1; the disease is skin neoplasm.